Hi, I’m Dr. Trevor P. Castor, Founder, President & CEO of Aphios Pharma LLC. I’m a UC Berkeley-trained chemical and mechanical engineer with more than 30 years of experience developing breakthrough biotechnology platforms and therapeutics.
At Aphios Pharma, we’re addressing a major unmet need in medicine: most CNS therapies don’t last long enough to effectively treat chronic conditions. Millions of patients suffering from opioid use disorder, chronic pain, anxiety, and other CNS disorders continue to relapse or fail therapy because current treatments have poor bioavailability and short duration of action.
We developed a proprietary extended-release nanoparticle platform designed to transform cannabinoids and other therapeutics into long-acting medicines. Our technology can deliver sustained therapeutic effects from 24 hours up to 30 days while significantly improving absorption, consistency, and patient compliance.
This is more than a single product opportunity — it’s a platform technology with the potential to improve how CNS drugs are delivered across multiple large markets.
We are initially focused on opioid use disorder, a multibillion-dollar market with urgent medical need and strong regulatory support for innovative therapies. Our lead programs combine cannabinoid science, nanotechnology, and scalable manufacturing to create differentiated therapeutics with the potential for superior clinical outcomes.
What makes Aphios unique is our foundation and execution. We have already invested more than $50 million into technology development, manufacturing infrastructure, and intellectual property, supported by over $20 million in NIH funding. Our platform is protected by a strong and expanding patent portfolio and supported by scalable, environmentally responsible manufacturing technologies.
Our business strategy is designed for multiple paths to value creation: near-term revenue opportunities, strategic licensing partnerships with pharmaceutical companies, and long-term potential through acquisition or public markets. Recent CNS and platform biotech transactions have demonstrated billion-dollar valuations for innovative therapeutic platforms like ours.
We are now raising $1 million through crowdfunding to advance clinical development, expand strategic partnerships, and position Aphios Pharma for significant growth.
Aphios Pharma is building a next-generation CNS therapeutics platform with multiple shots on goal and the potential for transformational impact — for patients and investors alike.
Join us on our journey!